MannKind Company Profile (NASDAQ:MNKD)

About MannKind (MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNKD
  • CUSIP: 56400P20
Key Metrics:
  • Previous Close: $0.90
  • 50 Day Moving Average: $1.65
  • 200 Day Moving Average: $0.86
  • 52-Week Range: $0.85 - $8.50
  • Trailing P/E Ratio: 0.66
  • Foreward P/E Ratio: -0.98
  • P/E Growth: -0.05
  • Market Cap: $86.20M
  • Outstanding Shares: 95,776,000
  • Beta: 3.26
Profitability:
  • Return on Equity: -15.95%
  • Return on Assets: 46.57%
Debt:
  • Debt-to-Equity Ratio: -0.62%
  • Current Ratio: 0.46%
  • Quick Ratio: 0.41%

Analyst Ratings

Consensus Ratings for MannKind (NASDAQ:MNKD) (?)
Ratings Breakdown: 3 Sell Ratings, 1 Hold Rating
Consensus Rating:Sell (Score: 1.25)
Consensus Price Target: $0.32 (64.81% downside)

Analysts' Ratings History for MannKind (NASDAQ:MNKD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/28/2017Piper Jaffray CompaniesReiterated RatingUnderweightN/AView Rating Details
11/11/2016JPMorgan Chase & Co.Reiterated RatingUnderweightN/AView Rating Details
8/31/2016S&P Equity ResearchLower Price Target$0.84 -> $0.70N/AView Rating Details
6/1/2016Royal Bank of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs Group IncReiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00N/AView Rating Details
5/11/2015MLV & Co.Lower Price TargetHold$7.00 -> $4.00N/AView Rating Details
(Data available from 4/24/2015 forward)

Earnings

Earnings History for MannKind (NASDAQ:MNKD)
Earnings by Quarter for MannKind (NASDAQ:MNKD)
Earnings History by Quarter for MannKind (NASDAQ:MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MannKind (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS

Dividends

Dividend History for MannKind (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MannKind (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%
Institutional Ownership Percentage: 19.71%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MannKind (NASDAQ:MNKD)
Latest Headlines for MannKind (NASDAQ:MNKD)
Source:
DateHeadline
americanbankingnews.com logo$0.12 EPS Expected for MannKind Co. (MNKD) This Quarter
www.americanbankingnews.com - April 25 at 12:26 AM
americanbankingnews.com logoMannKind (MNKD) Earns Coverage Optimism Score of 0.09
www.americanbankingnews.com - April 21 at 9:54 PM
americanbankingnews.com logoMannKind Co. (MNKD) Short Interest Update
www.americanbankingnews.com - April 19 at 6:56 PM
reuters.com logoBRIEF-Mannkind's unit entered exchange agreement
www.reuters.com - April 19 at 10:31 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Impact MannKind (MNKD) Share Price
www.americanbankingnews.com - April 18 at 6:05 PM
americanbankingnews.com logoVery Favorable News Coverage Very Likely to Impact MannKind (MNKD) Share Price
www.americanbankingnews.com - April 14 at 10:54 AM
fool.com logoIs MannKind Corporation Getting Ready to Sell?
www.fool.com - April 10 at 4:50 PM
finance.yahoo.com logoConatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand
finance.yahoo.com - April 3 at 10:12 AM
americanbankingnews.com logoShort Interest in MannKind Co. (MNKD) Declines By 5.9%
www.americanbankingnews.com - March 27 at 7:47 AM
finance.yahoo.com logoMANNKIND CORP Financials
finance.yahoo.com - March 23 at 7:07 PM
fool.com logoBillionaires' Worst Healthcare Stock Picks for 2017 (So Far)
www.fool.com - March 22 at 9:25 AM
fool.com logoCould MannKind Corporation's Marketing Blitz Pay Off?
www.fool.com - March 21 at 4:25 PM
finance.yahoo.com logoJefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now
finance.yahoo.com - March 20 at 10:12 AM
finance.yahoo.com logoEdited Transcript of MNKD earnings conference call or presentation 16-Mar-17 9:00pm GMT
finance.yahoo.com - March 17 at 6:45 PM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Other Events
biz.yahoo.com - March 17 at 6:45 PM
americanbankingnews.com logoMannKind Co. (MNKD) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:21 PM
marketwatch.com logo10-K: MANNKIND CORP
www.marketwatch.com - March 16 at 7:19 PM
us.rd.yahoo.com logoMannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results
us.rd.yahoo.com - March 16 at 7:19 PM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:19 PM
seekingalpha.com logoMannKind beats by $0.76, beats on revenue
seekingalpha.com - March 16 at 5:42 PM
biz.yahoo.com logoQ4 2016 MannKind Corp Earnings Release - Before Market Open
biz.yahoo.com - March 16 at 9:14 AM
seekingalpha.com logoMannKind's (MNKD) CEO Matt Pfeffer Presents At 29th Annual ROTH Conference (Transcript) - Seeking Alpha
seekingalpha.com - March 15 at 6:47 PM
fool.com logoBetter Buy: MannKind Corp. vs. Dexcom -- The Motley Fool - Motley Fool
www.fool.com - March 11 at 8:03 AM
seekingalpha.com logoMannKind Needs To Boost Script Sales - Will A Television Show Help? - Seeking Alpha
seekingalpha.com - March 11 at 8:03 AM
americanbankingnews.com logoMannKind Co. (MNKD) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 10 at 11:04 AM
fool.com logoBetter Buy: MannKind Corp. vs. Dexcom
www.fool.com - March 9 at 10:27 AM
finance.yahoo.com logoMannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes
finance.yahoo.com - March 8 at 10:01 AM
fool.com logoHere's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
www.fool.com - March 7 at 1:17 PM
finance.yahoo.com logoMannKind Corporation Announces Upcoming Events
finance.yahoo.com - March 7 at 10:22 AM
seekingalpha.com logoReverse split gets company compliant with Nasdaq. - Seeking Alpha
seekingalpha.com - March 3 at 6:37 PM
investorplace.com logoMannKind Corporation (MNKD) Stock Sinks on Reverse Stock Split Plans
investorplace.com - March 3 at 5:21 PM
fool.com logoWhy MannKind Corporation Stock Is Sinking Today
www.fool.com - March 3 at 12:21 PM
seekingalpha.com logoPost-split trading in MannKind commences today
seekingalpha.com - March 3 at 10:10 AM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matt
biz.yahoo.com - March 2 at 9:29 AM
blogs.barrons.com logoCan MannKind Be Saved?
blogs.barrons.com - February 27 at 6:04 PM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
biz.yahoo.com - February 23 at 6:40 PM
nasdaq.com logoNotable Wednesday Option Activity: AAWW, MNKD, TREX
www.nasdaq.com - February 22 at 6:44 PM
finance.yahoo.com logoMannKind Receives $16.7 Million From Sale of Valencia Property
finance.yahoo.com - February 21 at 6:21 PM
finance.yahoo.com logo9:03 am Mannkind receives $16.7 mln upon closing the sale of real estate owned by the co in Valencia, California, net of closing costs
finance.yahoo.com - February 21 at 6:21 PM
seekingalpha.com logoMannKind - Afrezza Sales Slip As New Sales Force Starts - Seeking Alpha
seekingalpha.com - February 19 at 5:40 PM
seekingalpha.com logoMannKind, Afrezza Sales, And 'Free Beer Tomorrow' - Seeking Alpha
seekingalpha.com - February 11 at 6:42 PM
fool.com logoHere's Why MannKind Corporation Rose 11.5% in January - Motley Fool
www.fool.com - February 7 at 7:38 AM
fool.com logoHere's Why MannKind Corporation Rose 11.5% in January
www.fool.com - February 6 at 10:11 AM
seekingalpha.com logoMannKind: The Saga Of Smoking Guns
seekingalpha.com - February 3 at 7:18 PM
streetinsider.com logoForm 5 MANNKIND CORP For: Dec 31 Filed by: KRESA KENT
www.streetinsider.com - February 3 at 5:28 AM
fool.com logoGood News and Bad News for MannKind Corporation
www.fool.com - February 2 at 7:25 PM
thestreet.com logoMannkind in Free Fall After Changes to Insulin Product, Sales Force
www.thestreet.com - February 2 at 7:25 PM
fool.com logoHere's Why MannKind Corporation Is Plunging
www.fool.com - February 2 at 7:25 PM
investopedia.com logoMannKind Looks to Boost Flagging Afrezza Sales
www.investopedia.com - February 2 at 7:25 PM
seekingalpha.com logoMannKind refines commercial approach for Afrezza; reverse stock split proposed; shares down 16%
seekingalpha.com - February 2 at 1:19 PM

Social

Frequently Asked Questions for MannKind (NASDAQ:MNKD)

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Thursday, March, 16th. The company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.01. The company earned $12.40 million during the quarter, compared to the consensus estimate of $6 million. MannKind's revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.30) earnings per share.

When will MannKind make its next earnings announcement?

MannKind is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Where is MannKind's stock going? Where will MannKind's stock price be in 2017?

4 analysts have issued 12 month target prices for MannKind's shares. Their forecasts range from $0.10 to $0.70. On average, they expect MannKind's share price to reach $0.32 in the next year.

Are investors shorting MannKind?

MannKind saw a decline in short interest in March. As of March 31st, there was short interest totalling 19,490,324 shares, a decline of 1.5% from the March 15th total of 19,793,968 shares. Based on an average trading volume of 1,796,589 shares, the days-to-cover ratio is presently 10.8 days.

Who owns MannKind stock?

MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (5.17%). Company insiders that own MannKind stock include Hakan Edstrom, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MannKind stock cost?

One share of MannKind stock can currently be purchased for approximately $0.90.

MannKind (MNKD) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by MarketBeat.com Staff